Madely Health Headlines Commentary for March , 2013
The results were presented at the American Academy of Neurology’s 65th Annual Meeting. It is not published.
Further it compares the drug to placebo, a useless marker for clinicians. We want to know how it fares against other medication of a similar class at least and how it compares to other medication in use today. It also refers to relative and not absolute risk reduction.